Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”). The offering was priced at $28.50 per share, and the company received gross proceeds of approximately $450.0 million, before deducting underwriting discounts, commissions and other offering expenses payable by the company.
Jefferies, BofA Securities and TD Cowen acted as bookrunning managers for the offering. Piper Sandler and RBC Capital Markets acted as capital markets advisors for the offering. Arrowhead intends to use the net proceeds from this offering for research and development, general corporate expenses and working capital needs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.